PDD as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This meeting will bring together researchers performing or interested in phenotypic drug discovery (PDD) from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. The previous two PDD Keystone Symposia, in 2016 and 2019, were tremendously received, and we have determined that there is ample enthusiasm for hosting another Keystone Symposium on this evolving topic. Our goals in this meeting are to 1) share information and best practices in new PDD technologies, biological models, and human disease areas; 2) foster collaborative discussions across academia and industry; and 3) address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). We anticipate that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.
https://www.nature.com/naturecareers/events/event/keystone-symposia-95432
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics
